BR9610967A - Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele - Google Patents

Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele

Info

Publication number
BR9610967A
BR9610967A BR9610967A BR9610967A BR9610967A BR 9610967 A BR9610967 A BR 9610967A BR 9610967 A BR9610967 A BR 9610967A BR 9610967 A BR9610967 A BR 9610967A BR 9610967 A BR9610967 A BR 9610967A
Authority
BR
Brazil
Prior art keywords
prevent
skin aging
cosmetic process
ligand specific
type receptors
Prior art date
Application number
BR9610967A
Other languages
English (en)
Inventor
Laszio Fesus
Zsuzza Szondy
Uwe Reichert
Original Assignee
Cird Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird Galderma filed Critical Cird Galderma
Publication of BR9610967A publication Critical patent/BR9610967A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BR9610967A 1995-10-09 1996-10-08 Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele BR9610967A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE

Publications (1)

Publication Number Publication Date
BR9610967A true BR9610967A (pt) 1999-03-02

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610967A BR9610967A (pt) 1995-10-09 1996-10-08 Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele

Country Status (16)

Country Link
US (4) US6593359B1 (pt)
EP (1) EP0854710A2 (pt)
JP (1) JP3135266B2 (pt)
KR (1) KR19990064139A (pt)
CN (1) CN1121857C (pt)
AU (1) AU705993B2 (pt)
BR (1) BR9610967A (pt)
CA (1) CA2231561A1 (pt)
FR (1) FR2739557B1 (pt)
HU (1) HUP9900453A3 (pt)
NO (1) NO981592L (pt)
NZ (1) NZ319646A (pt)
PL (1) PL185826B1 (pt)
RU (1) RU2188037C2 (pt)
TR (1) TR199800645T1 (pt)
WO (1) WO1997013505A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
WO1999024024A2 (en) 1997-11-12 1999-05-20 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
WO2004050101A2 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
EP1727516B1 (en) * 2004-03-26 2014-05-14 DSM IP Assets B.V. Composition comprising an hdac inhibitor in combination with a retinoid
US7713266B2 (en) * 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) * 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
WO2010075438A1 (en) 2008-12-22 2010-07-01 Myoscience, Inc. Integrated cryosurgical system with refrigerant and electrical power source
EP2613776B1 (en) * 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
CN103732231B (zh) * 2011-06-24 2020-04-10 格里生物公司 炎性病症的预防和治疗
EP2802278B1 (en) 2012-01-13 2016-12-07 Myoscience, Inc. Cryogenic probe filtration system
BR112014017175A8 (pt) 2012-01-13 2017-07-04 Myoscience Inc proteção de pele para remodelagem criogênica subdérmica para tratamentos cosméticos e outros
US9314290B2 (en) 2012-01-13 2016-04-19 Myoscience, Inc. Cryogenic needle with freeze zone regulation
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
US20140350536A1 (en) 2013-03-15 2014-11-27 Myoscience, Inc. Cryogenic Blunt Dissection Methods and Devices
WO2014146122A1 (en) 2013-03-15 2014-09-18 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
EP4098257A1 (en) 2015-11-25 2022-12-07 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
US11311327B2 (en) 2016-05-13 2022-04-26 Pacira Cryotech, Inc. Methods and systems for locating and treating nerves with cold therapy
CN115671292A (zh) 2016-06-10 2023-02-03 Io治疗公司 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
IL302133A (en) 2017-07-13 2023-06-01 Io Therapeutics Inc A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
US11134998B2 (en) 2017-11-15 2021-10-05 Pacira Cryotech, Inc. Integrated cold therapy and electrical stimulation systems for locating and treating nerves and associated methods
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
EP0850067A4 (en) * 1995-07-17 1999-12-15 Cird Galderma METHOD FOR CANCER TREATMENT USING 6- (3- (1-ADAMANTYL) -4-HYDROXYPHENYL) 2 NAPHTALINE CARBONIC ACID

Also Published As

Publication number Publication date
NZ319646A (en) 2000-08-25
NO981592L (no) 1998-06-09
US20010018456A1 (en) 2001-08-30
HUP9900453A2 (hu) 1999-05-28
EP0854710A2 (fr) 1998-07-29
PL185826B1 (pl) 2003-08-29
CN1203528A (zh) 1998-12-30
AU705993B2 (en) 1999-06-03
NO981592D0 (no) 1998-04-07
CA2231561A1 (fr) 1997-04-17
US6506796B1 (en) 2003-01-14
AU7220996A (en) 1997-04-30
JPH11501661A (ja) 1999-02-09
WO1997013505A3 (fr) 1997-05-29
CN1121857C (zh) 2003-09-24
KR19990064139A (ko) 1999-07-26
FR2739557B1 (fr) 1997-11-14
RU2188037C2 (ru) 2002-08-27
US6686386B1 (en) 2004-02-03
JP3135266B2 (ja) 2001-02-13
PL326077A1 (en) 1998-08-17
FR2739557A1 (fr) 1997-04-11
US6593359B1 (en) 2003-07-15
WO1997013505A2 (fr) 1997-04-17
HUP9900453A3 (en) 1999-11-29
TR199800645T1 (xx) 1998-06-22

Similar Documents

Publication Publication Date Title
BR9610967A (pt) Utilização de pelo menos um ligante agonista específico aos receptores de tipo rar e processo cosmético para previnir e/ou combater o envelhecimento fotoinduzido ou cronológico da pele
BR9702673A (pt) Composição de aplicação tópica composição solar e/ou de maquilagem da pele utilização cosmética da composição utilização de um organopolissiloxano processo cosmético para a fotoproteção e processo cosmético para combater o envelhecimento foto-induzido
BR9600628A (pt) Emulsão óleo-em-água transparente composição de uso tópico uso de emulsão processo de tratamento não terapêutico da pele e/ou do couro cabeludo e processo de preparação de uma emulsão
BR9801355A (pt) Emulsão óleo-em-água composição cosmética de uso tópico utilização de uma emulsão processo de tratamento não terapéutico da pele e processo de preparação de uma emulsão
BR9004038A (pt) Composicao adequada para aplicacao topica a pele e cabelo de mamiferos
BR9607287A (pt) Polímero de melanina processo para obter o mesmo e processo para produzir um bronzeado de aparência natural na pele de mamíferos
BR9600581A (pt) Aplicador dosador capilar conjunto para tratamento ou maquiagem e conjunto para tratamento ou maquiagem dos olhos
BR9302360A (pt) Composicao cosmetica e processo para conferir um bronzeado a pele
BR9706326A (pt) Composição para maquilagem ou proteção não migrável batom ou base anidra n o migrável uso de uma organopolissiloxana elastorérica sólida pelo menos parciamente reticulada processo para limitar e/ou impedir a migração de uma composição e processo de tratamento cosmético
BR7806143A (pt) Composicao cosmetica destinada ao tratamento dos cabelos ou da pele,composto para a mesma,e processo aplicado a mesma
BR8903526A (pt) Composicao de lubrificantes e aplicacao
BR9708362A (pt) Utilização de uma quantidade eficaz de um extrato e processo de tratamento cosmético
BR7804961A (pt) Composicao de revestimento aquosa cataforeticamente depositavel,e processos para sua preparacao e sua aplicacao
BR8906832A (pt) Composicao e processo para combater insetos
BR9800660A (pt) Emulsão água-em-óleo sua utilização composição cosmética e/ou dermatológica processo de tratamento cosmético e utilzação de uma associação
BR9601404A (pt) Composição de limpeza e condicionamento combinados e processo de limpeza e condicionamento concomitantes da pele ou dos cabelos
BR7906997A (pt) Preparado cosmetico,processo para a fabricacao de compostos,processo para a fabricacao de um preparado cosmetico,processo para a protecao da pele ou do cabelo,e aplicacao dos ditos compostos
BR9505626A (pt) Revestimento de pó de efeito processo para sua preparação e uso
BR7802699A (pt) Composicao para o combate de ectoparasitas e sua aplicacao
BR7801931A (pt) Processo e composicao para tratar cabelo
BR8502971A (pt) Composicoes cosmeticas que permitem retardar a aparicao do aspecto oleoso dos cabelos,utilizacao e processo para o tratamento dos cabelos
BR7802654A (pt) Composicoes cosmeticas de cabelo e processo para tratamento cosmetico
DE69720613D1 (de) Neue topische Zusammensetzungen, die Melatonin oder seine Analogen in sehr niedrigen Dosen enthalten, und ihre Verwendung in der Kosmetik
BR9609930A (pt) Mistura fungicida processo para controlar fungos nocivos e uso dos compostos
BR8105108A (pt) Composicao de tingimento e processo para o tingimento de cabelos humanos

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.